Analyst Josh Jennings from TD Cowen maintained a Buy rating on Cerus and keeping the price target at $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Josh Jennings has given his Buy rating due to a combination of factors related to Cerus’s recent achievements in regulatory progress. The company has successfully advanced its INTERCEPT Red Blood Cells (RBC) system through a significant EU regulatory milestone, with TUV-SUD completing the review of the clinical module for the CE Mark submission.
This advancement is noteworthy as it has been achieved ahead of Cerus’s internal timelines by several weeks, indicating strong momentum in their regulatory efforts. The dossier’s transfer to the State Institute for Drug Control in the Czech Republic for further evaluation suggests that Cerus is on track to potentially secure CE Mark approval by the second half of 2026. This progress under the European Medical Device Regulation framework highlights Cerus’s potential to tap into the substantial EU commercial opportunity, which is a part of the multi-billion dollar global RBC total addressable market.
Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Abbott Laboratories, and Medtronic. According to TipRanks, Jennings has an average return of 3.8% and a 51.31% success rate on recommended stocks.